Welcome to our dedicated page for Gerresheimer news (Ticker: GRRMY), a resource for investors and traders seeking the latest updates and insights on Gerresheimer stock.
Gerresheimer AG (GRRMY) delivers essential solutions for pharmaceutical containment, drug delivery systems, and medical technologies across 36 global production sites. This news hub provides investors and industry stakeholders with timely updates on corporate milestones, financial performance, and innovations shaping healthcare markets.
Access official press releases covering earnings announcements, strategic partnerships, product launches, and sustainability achievements like the company's EcoVadis Gold recognition. Our curated collection enables efficient tracking of operational developments in pharma packaging, digital health solutions, and biotech collaborations.
Bookmark this page for direct access to Gerresheimer's latest regulatory disclosures, market expansion updates, and CSR progress reports. Stay informed about material events impacting one of Europe's leading providers of medical-grade containment systems and therapeutic support technologies.
Gerresheimer AG reported a strong start to 2021, achieving revenues of EUR 303 million in Q1, a 3.1% increase year-on-year. Growth was driven by the Plastics & Devices Division, with a notable demand for syringes and pharmaceutical packaging. Adjusted EBITDA rose to EUR 54 million, reflecting a 29.3% year-on-year increase in adjusted earnings per share at EUR 0.57. The company forecasts mid single-digit revenue growth for 2021 and aims for an adjusted EBITDA margin of 22-23%. Gerresheimer is expanding production for Covid-19 vaccine vials, reinforcing its role in the pandemic response.
FAQ
What is the current stock price of Gerresheimer (GRRMY)?
What is the market cap of Gerresheimer (GRRMY)?
